Anti-Mouse Dendritic Cells – Purified in vivo PLATINUM™ Functional Grade

Pricing & Details

Product No.D212
Dendritic Cells
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
DC Marker, 33D1, DCIR2 (dendritic cell inhibitory receptor 2)
IgG2b κ
Prod No.
Add to cart
D212-1.0 mg
1.0 mg
In stock
Min: 1
Step: 1
D212-5.0 mg
5.0 mg
In stock
Min: 1
Step: 1
D212-25 mg
25 mg
In stock
Min: 1
Step: 1
D212-50 mg
50 mg
In stock
Min: 1
Step: 1
D212-100 mg
100 mg
In stock
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Host Species
Dendritic cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for clone 33D1 antibody for staining cells in flow cytometry is ≤ .25 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone 33D1 recognizes mouse DCIR2.
Antigen Distribution
Murine DCIR2 is found on dendritic cells of the thymus, spleen, lymph nodes, and Peyer’s patches. DCs in the bone marrow may express DCIR2 in the presence of GM-CSF. However, this expression is notably downregulated when IL-4 is present. Furthermore, DCIR2 has been found In vivo on brain dendritic cells post infection with T. gondii.
Dendritic cells are antigen presenting cells that have two functions. They scan the body collecting and processing antigen material that they present on the cell surface to T cells, and they maintain T cell tolerance to “self”. The morphology of dendritic cells is characterized by an extremely large surface-to-volume ratio. Murine splenic dendritic cells can occur in two types: myeloid (cDC) and lymphoid (pDC). Lymphoid dendritic cells produce high amounts of IFN-α and are also called Plasmacytoid dendritic cell because they have an appearance similar to plasma cells. Myeloid, or conventional dendritic cells, secrete IL-12, IL-6, TNF, and chemokines and can be further categorized into three subtypes (CD4−CD8+, CD4+CD8− and CD4−CD8−). These differ from other migratory dendritic cells such as Langerhans cells and interstitial dendritic cells that migrate from peripheral tissues to the lymph nodes. The exact nature and biological activity of the dendritic cell surface marker DCIR2 is currently unknown. DCs are known to play a role in several diseases including myeloid cancer, pDC leukemia, HIV, lupus erythematosus, Crohn's disease and ulcerative colitis. However, it is thought that DCs may be able to control cancer progression because increased densities of DC populations have been linked with better clinical outcome. Lung cancers have been found to include four different subsets of dendritic cells; some of which can activate immune cells that can suppress tumor growth. Dendritic cells have also been shown to play a role in the success of cancer immunotherapies in experimental models. Specifically, the immune checkpoint blocker anti-PD-1 has been shown to indirectly activate DCs through IFN-γ released from drug-activated T cells. Agonizing the non-canonical NF-κB pathway also activates DCs and further enhances anti-PD-1 therapy in an IL-12-dependent manner.

Antigen Details

GM-CSF is reported to increase expression of 33D1 antigen on dendritic cells from bone marrow cells and IL-4 reported to down regulate the 33D1 antigen.
Research Area

References & Citations

Steinman, R. M. et al. (1982) Pro. Natl. Acad. Sci. USA 79:161 Steinman, R. M. et al. (1983) J. Exp. Med. 157:613 Nussenzweig et al. 1982. Proc Natl Acad Sci U S A. 79(1):161-5. PMID: 6948298.
General Western Blot Protocol

Formats Available